Granisetron Hydrochloride - CAS# 107007-99-8 10549 and the Kd for recombinant

and the Kd for recombinant UCHL5 is higher (14-18 μM) compared to that of USP14

which is (R)-enantiomer of the drug

146(231)197-121)198-135(220)106(51-38-68-175-152(166)167)185-137(222)116-54-41-71-202(116)143(228)113(76-94-80-177-100-45-29-27-43-98(94)100)192-128(213)103(48-35-65-172-149(160)161)183-126(211)102(181-91(15)203)47-34-64-171-148(158)159)145(230)193-111(77-95-81-168-82-178-95)134(219)195-119(85(7)8)139(224)186-104(49-36-66-173-150(162)163)127(212)184-105(50-37-67-174-151(164)165)129(214)194-120(86(9)10)140(225)191-110(75-93-79-176-99-44-28-26-42-97(93)99)132(217)182-101(46-33-63-170-147(156)157)125(210)169-62-32-24-25-55-117(205)179-89(13)124(209)187-107(72-83(3)4)130(215)180-90(14)142(227)201-70-40-53-115(201)138(223)189-109(74-92-56-58-96(204)59-57-92)133(218)196-122(88(12)19-2)144(229)200-69-39-52-114(200)123(155)208/h20-21

Formula: C25H26F6N2O2

In the p21-intact Hct116 xenografts in nude mice

Granisetron Hydrochloride - CAS# 107007-99-8 10549 and the Kd for recombinantGranisetron hydrochloride is the hydrochloride salt of an indazole derivative with antiemetic properties. As a selective serotonin receptor antagonist, granisetron competitively blocks the action of serotonin at 5 hydroxytryptamine3 (5 HT3) receptors, resulting in the suppression of chemotherapy and radiotherapy induced nausea and vomiting. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus). Product